VASCADE MVP and MVP XL closure devices for walking sooner after catheter-based heart procedures

You may qualify if

• ≥18 years of age
• Capable and willing to give informed consent
• Candidate for an elective, non-emergent catheter-based procedure via the common femoral vein
• Eligible and planned same day discharge
• Able and willing to complete Patient Experience questionnaire and standard of care follow-up (2 week automated phone call and 30-Day +/- 14 days follow-up in-person or telemed visit).

You can't join if

• Currently involved in any other investigational clinical trial that may interfere with the outcomes of this study, in the opinion of the Investigator
• Pre-existing immunodeficiency disorder and/or chronic use of high dose systemic steroids
• Known history of bleeding diathesis, bleeding problems following medical procedures, or coagulopathy
• Known baseline hemoglobin < 10 g/dl, hematocrit < 30%, platelet count < 100,000 cells/mm3
• Severe co-existing morbidities, with a life expectancy of less than 12 months in the opinion of the Investigator
• Known history of deep vein thrombosis or pulmonary embolism in the last 12 months
• Known allergy/adverse reaction to bovine derivatives
• Active systemic infection, or cutaneous infection or inflammation in the vicinity of the groin
• Unable to ambulate at least 20 ft at baseline
• Pregnant (known or suspected) or lactating
• Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20 kg/m2)
• Known planned procedures or known concomitant condition(s) that may extend ambulation attempts beyond 2-4 hours, and/or hospitalization time (e.g., staged procedure, serious co-morbidity), in the opinion of the Investigator
• Femoral vessel closure in either limb with any of the following conditions:; Planned femoral access in the next 60 days to reflect the device re-access period; Any residual hematoma, significant bruising, or known associated vascular complications; Use of an intra-vascular closure device within the previous 90 days; Access within < 10 days
• Currently known implanted vascular grafts/stents at the access site that would interfere with the planned closure procedure, in the opinion of the Investigator -